P05.06 Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O(6)-methylguanine-methyltransferase (MGMT) promoter status

BACKGROUND: GDC-0084 is a potent, oral, selective small molecule inhibitor of class I phosphoinositide 3-kinase and mammalian target of rapamycin (PI3K/mTOR). The PI3K pathway is activated in ≥ 70% of tumors, making it a compelling target for the treatment of GBM. GDC-0084 crosses the blood-brain ba...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Wen, P Y, de Groot, J, Battiste, J D, Goldlust, S A, Garner, J, Simpson, J, Olivero, A, Cloughesy, T
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2019
Предметы:
Poster Presentations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796036/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.120
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы